cyrilzakka/clinical-trials huggingface dataset:
Influence of Tart Cherry Juice Intervention on Vascular Function

Diets containing fruit rich in anthocyanins have been shown (in meta-analyses) to be beneficial for health, but intervention trials have shown inconsistent results. In this preliminary study we want to investigate the influence of a tart-cherry juice intervention on vascular function and explore metabolite profiles that may offer insight into their mechanism of action

Cardiovascular disease (CVD) is the primary cause of morbidity and mortality. Tart cherries (TC) can positively impact major risk factors of CVD, activities thought to be related to their phytochemical content. However, data from human trials is less clear. TC have been shown to reduce systolic blood pressure (SBP) after acute, short-term and chronic intake, and to improve vascular dysfunction, presumably due to their antioxidant and anti-inflammatory activities. Other studies have not shown benefits of TC on SBP or vascular function and studies are difficult to interpret with different populations, dosing and durations being used as well as a lack of understanding for any underlying mechanisms. To account for the latter, the use of metabolomics has become increasingly popular in nutritional research. Therefore, the aim of this preliminary study was to characterise the effects of TC supplementation on vascular function with a 4-week intervention and explore if metabolomics can provide mechanistic evidence and this will inform for future chronic studies with TC juice.

Eligibility Criteria:
Inclusion Criteria:

* aged 19-40
* no diagnosed issues with the ability to consume fruit juice
* no known food intolerances to fruits

Exclusion Criteria:

* participants that are cigarette smokers
* participants diagnosed with hypertension
* participants diagnosed with any form of cardiometabolic diseases
* participants that require any prescribed prescriptions excluding the contraceptive pill
* participants that are regular consumers of cherries (\>100 g/d)
* participants that consume any antioxidant supplements
The Effect of Perthes' Disease on Hip Cartilage

The purpose of this study is to determine whether Perthes' disease has caused detectable hip cartilage damage in young people who have reached the healed stage of the disease.

We will recruit 20 subjects from our healed Perthes' population. We will use dGEMRIC imaging to identify regions of cartilage degeneration in the femur and acetabulum. Both hips will be imaged so that we can use the unaffected side as a control. We will apply dGEMRIC imaging, which allows the composition of cartilage (specifically, the concentration of glycosaminoglycans \[GAGs\], important structural proteins in the cartilage) to be assessed.

The MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- \[Gd-DTPA2-\] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging. Due to the need to image within a relatively narrow window of time, each hip of each subject must be imaged on separate days. The subject will be asked to walk for 10 minutes after receiving the contrast agent injection to facilitate equilibration of contrast agent into the hip joint.

The scans will be performed at UBC's High Field Imaging Centre on the 3T Phillips Intera scanner. Dr. Wilson has access to this scanner for his research. The scanning protocol is as follows: 3D IR-TFE sequence with TR/TE/Flip of 4.7 ms/1.6 ms/30 o and seven inversion times; 1600, 1200, 800, 400, 200, 300, and 100 ms. In-plane resolution is 0.7 mm with a slice thickness of 3 mm. Total imaging time is approximately 1 hour (at each visit). The T1 calculated image will be obtained using validated, custom written software (IGOR). The resulting image provides a map approximating glycosaminoglycan concentration and, consequently, cartilage degeneration.

The MRI will not be done under sedation. MRIs are performed under sedation at BCCH for children under age seven. Subjects in this study will be between the ages of 7 and 18. The contrast agent, Gd-DTPA2- is routinely used in children in the clinical setting.

Radiographs used for comparison are obtained as part of standard of care follow-up protocol.

Eligibility Criteria:
Inclusion Criteria:

* Subjects must have reached the healed stage of unilateral Perthes' disease. -Subjects will be between 7 and 18 years of age.
* Subjects must understand English.

Exclusion Criteria:

* Subjects will be excluded if they have bilateral Perthes' disease or if they have not yet reached the healing stage of the disease.
* Subjects will also be excluded if they do not meet the criteria to have an MRI (e.g., the subject has metal implants, is claustrophobic, has a metallic object in eye or a pacemaker).
* A subject will be excluded if they have any of the precautions for the MR contrast agent, Magnevist, such as pregnancy, breast-feeding, respiratory allergies, asthma, thrombotic syndromes, history of grand mal seizures, impaired renal or hepatic function.
Effect of Different Exercises on Quality of Life of Leukemia Patients.

* To compare between modified strength training program and aerobic exercises on quality of life on children with Acute Lymphoblastic Leukemia.
* To compare between modified strength training program and aerobic exercises on functional capacity on children with Acute Lymphoblastic Leukemia.

This study will be done to determine any exercise from aerobic exercises or modified strength training program will be more effective on quality of life and functional capacity on children with Acute Lymphoblastic Leukemia .Acute Lymphoblastic Leukemia is wide spread in the world and the children with this disease are fragile so must know the most program effect.

Eligibility Criteria:
Inclusion Criteria:

* Age range from8-12years.
* Children during 3rd phase( maintenance phase of the treatment). According San et al(2007) who found children with Acute Lymphoblastic Leukemia in maintenance phase of treatment can safely perform both aerobic and resistance training .
* Time elapsed since the start of the maintenance phase \>20weeks.
* Children with muscle weakness due to chemotherapy.
* The height , weight and body mass index of the child will take on standard scale.
* preserved cardiac structure and function as assisted by echo-cardiogram.
* The children have ability to walk.

Exclusion Criteria:

Children who have one or more of the following criteria will be excluded from the study:

* Receiving more intensive chemotherapy.
* Mental disabled.
* Sever cardiomyopathy (ejection fraction \<40%, ECG will be used as a pretest as it might be a more sensitive tool to exclude angina pectoris).
* Low blood platelet levels (\< 50.000 per µl).
* Marked anemia (hemoglobin \< 8 g/dl).
* Severe cachexia (i.e., weight mass loss \> 35%).
* Pain in bone.
* Inability to walk.
* Sensory disturbance.
* Peripheral neuropathy.
Turkish Version of Telehealth Satisfaction Survey (TeSS)

The Turkish validity and reliability of the scale, which was created to evaluate the satisfaction of individuals, caregivers, and coordinator providing telerehabilitation services within the scope of telehealth, will be investigated.

The telehealth satisfaction survey (TeSS) has been developed according to expectations, taking into account a device previously used in telehealth studies in Saskatchewan. The scale was initially used as part of a national study to evaluate the use of telehealth practices in improving professional access by residents of isolated Northern First Nations communities.The scale designed for telehealth services has been developed in English. Validity and reliability studies have been carried out by being translated into various languages. The Turkish validity and reliability study of the scale, originally in English, has not been conducted before.

Eligibility Criteria:
Inclusion Criteria:

* Men and woman who used telehealth

Exclusion Criteria:

* Individuals who have the poor cooperation Mini-Mental State Exam scores of under 23
Pilot Study Comparing Ventilation Modes During CPR With Mechanical Compression Device.

Comparison of three ventilation modes (volume controlled, BIPAP and CPAP) during cardiopulmonary re-suscitation with a mechanical compression device in the emergency room. Primary aim is to assess mean ventilation volume in the first 15 minutes after randomization.

Mechanical compression devices are applied to grant continuous chest compressions and consequently blood flow during CPR (cardiopulmonary rescuscitation). Current guidelines, however, are lacking guidance of the optimal ventilation strategy in such scenarios. This may lead to lung injuries caused by high pressure levels in the chest while applying compression and ventilation simultaneously or hypoventilation. Consequently, this pilot study assesses iwhich ventilation mode is optimal. Patients will be assigned randomly to one of the three ventilation modes (Volume controlled, BiPAP-ASB, CPAP). Ventilation parameters will be continuously monitored for 15 minutes while blood gas analyses are taken as well. Further secondary outcome parameters will be assessed, e.g. hospital mortality.

Eligibility Criteria:
Inclusion Criteria:

* On-going out of hospital CPR in the Emergency Room
* Tracheal intubated
* Use of mechanical chest compression device

Exclusion Criteria:

* If the treating team assumes that CPR will be ceased within the next 15 minutes
Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study

The purpose of this study is to determine whether two new airway devices used during anesthesia called iGEL™ and KING-LTS-DTM work well and are safe in obese patients. They both work well in thin patients, but have not been tested in obese patients.


Eligibility Criteria:
Inclusion Criteria:

* Scheduled for elective surgery with an estimated duration of 30 to 120 minutes
* American Society of Anesthesiologists (ASA) status I-III
* Aged 18 to 65 years.
* Body mass index (BMI) ≥ 35 kg/m2

Exclusion Criteria:

* A history of difficult intubation;
* Immobilized cervical spine;
* Oxygen saturation less than 95% at room air;
* A history of uncontrolled gastroesophageal reflux or hiatus hernia;
* A history of ulcer surgery including vagotomy;
* Previous gastric bypass surgery;
* Diabetic gastroparesis;
* Patients with known coagulation disorders (e.g. hemophilias, von Willebrand disease, factor V leiden diseases) or on systemic anticoagulation drugs (e.g. continuous heparin infusion); Patients with abnormal coagulation tests will be also excluded. However, asymptomatic patients will not be tested on any coagulation disorders.
* Any pathologies of the mouth, pharynx or larynx, the access to the airway is restricted, or a difficult tracheal intubation is anticipated.
* Pregnant or breast-feeding (pregnancy status will be confirmed by a pregnancy test, as it is standard for all surgical procedures at the University hospital).
The Difference of Oropharyngeal Leak Pressure and Sealing Pressure Between New Supraglottic Airway Devices

The difference of oropharyngeal leak pressure and sealing pressure between new supraglottic airway devices.

In this clinical study, investigators want to discuss the issue that oropharyngeal leak pressure and sealing condition with different SGA including air-Q、i-gel、LMA-supreme、AMBU auragain 、ProSeal LMA and other new SGAs.

In the perioperative period, investigators documented respiratory function data including oropharyngeal leak pressure and peak airway pressure in these randomly selected SGA. Oropharyngeal leak pressure was measured by closing the expiratory valve of the circle system at fixed O2 flow 3L/min and noting the airway pressure at which the dial on a calibrated aneroid manometer reached equilibrium.

investigators wanted to compared the respiratory function between air-Q、i-gel、LMA-supreme、AMBU auragain、ProSeal LMA and other new SGAs during surgery and postoperative care unit.

Eligibility Criteria:
Inclusion criteria:

1. 20-80 years old.
2. ASA physical status I or II .
3. Without major organ dysfunction like heart, liver, brain, lung, kidney function failure.

Exclusion criteria:

1. BMI\> 35 kg/m2.
2. Risk of aspiration(NPO clear water\> 2 hours, solid foods \> 8 hours).
3. Difficult airway like head and neck tumor or airway tumor.
4. Limited mouth opening (\<2cm).
5. major organ dysfunction including heart, liver, brain, lung, kidney function failure.
6. Major surgery including open heart surgery, laparotomy general surgery, open chest surgery.
Pharmacokinetics of Omadacycline in Cystic Fibrosis

The purpose of this study is to characterize the pharmacokinetics of intravenous and oral omadacycline in patients with cystic fibrosis.

Omadacycline exhibits excellent activity against bacteria including methicillin-resistant Staphylococcus aureus (MRSA), Burkholderia cepacia, and Nontuberculous mycobacteria (NTM) that are a potential source of lung infection in CF patients. As omadacycline demonstrates antimicrobial activity against a number of pathogens in CF, the investigators hope to learn the optimal dose of omadacycline necessary to treat lung infections in patients with CF in the future. The study hypothesis is that omadacycline will exhibit good oral bioavailability in patients with CF.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of CF based on positive sweat chloride or known CF mutation
* Age \>=18 years

Exclusion Criteria:

* Presence of an ongoing acute pulmonary exacerbation defined based on clinical signs \& symptoms and an acute decline in relative FEV1 of 10% or greater.
* Pregnancy or breastfeeding
* Serious past allergy to a tetracycline antibiotic
* No alcohol, nicotine, or caffeine-containing products during the study period
* Hemoglobin \< 8 g/dL
Clinical Performance of Adhesive Systems Containing HEMA and 10-MDP in Non Carious Cervical Lesions

The objective of this randomized, double-blind clinical trial is to evaluate the clinical performance of non-carious cervicals adhesive restorations using three self-etching adhesives containing HEMA and 10-MDP monomers.

Sixty teeth (n = 20 for each group) will be randomized into 03 groups: Clearfil SE (contains MDP and HEMA), Optibond All-inOne (contains HEMA) and Prime and Bond Universal (contains neither monomer) dispatch). Restorations will be performed by a single operator, and no mechanical retention will be performed under the cavity. After 6, 12 and 24 months, the restorations will be evaluated by two calibrated examiners, using modified USPHS criteria for retention (kappa = 1.00) and adaptation / marginal color (kappa = 0.81), and the results will be analysed by Fisher and Kruskal-Wallis, respectively. An intragroup analysis will be performed using the Cochran test (for retention) and Wilcoxon (for marginal adaptation / staining).

Eligibility Criteria:
Inclusion Criteria:

* Good oral hygiene
* Absence of periodontal disease
* Presence of at least 02 non-carious cervical lesions

Exclusion Criteria:

* Presence of non-carious cervical lesion in non-vital teeth
* Occlusal instability
* Presence of orthodontic appliance
* Presence of removable partial dental prosthesis
* High risk of caries (presence of three or more active caries lesions)
* Xerostomia
* Bruxism
* Patients allergic to base materials monomers
* Patients who do not accept the project conditions
An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis

This is an open label, multi-center, multi-application pharmacokinetic study in pediatric subjects with tinea corporis.


Eligibility Criteria:
Inclusion Criteria:

* Male or females 2 to 11 years, 11 months of any race. Females of child producing age (started menarche) must have a negative urine pregnancy test.
* Presence of tinea corporis characterized by clinical evidence of a tinea infection at multiple sites covering a total of at least 1% body surface area.
* KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected of the overall severity.
* Subjects must be in good health and free from clinically significant disease that might interfere with the study evaluations.

Exclusion Criteria:

* Tinea infection of the scalp, face, groin, and/or feet.
* A life-threatening condition (ex. autoimmune deficiency syndrome, cancer) within the last 6 months
* Subject with abnormal findings-physically or laboratory- that considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
* Subjects with a known hypersensitivity or other contradictions to study medications or their components.
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer

In this study we aim to more precisely define the clinical utility of PSMA imaging across a range of clinical indications in men with prostate cancer. To accomplish this, we will make the 18F-DCFPyL PET/CT scan available to urologists, medical oncologists, and radiation oncologists at Johns Hopkins and survey physicians as to the indication for ordering the PET/CT and if a change in management occurred as the result of new information gained from the scan. We believe these data will prove critical for planning future studies aimed at evaluating the efficacy of this test for improving patient outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. Age ≥18 years
2. Willingness to signed informed consent
3. Histologically confirmed adenocarcinoma of the prostate
4. PSA measurement ≤60 days prior to study enrollment
5. Completed radiographic evaluation with whole-body bone scan (99mTc-MDP or Na18F) and cross-sectional imaging (CT or MRI) of the abdomen and pelvis ≤60 days prior to study enrollment

Exclusion Criteria:

1. Administered a radioisotope within 5 physical half-lives prior to study enrollment
2. History of other malignancy diagnosed within the last 5 years (exceptions: low grade urothelial carcinoma of the bladder, squamous cell carcinoma or basal cell carcinoma of the skin).
Imodium Syrup Versus Imodium Tablets for Faecal Incontinence

Faecal incontinence (FI) is a debilitating and often neglected problem. It can be defined as the loss of voluntary control of liquid or solid stool.It is estimated that 2-3% of western adults suffer from FI with prevalence increasing with age, further to this up to 50% of nursing home residents suffer too with it more common in females. Aetiology is often multi-factoral, where obstetric anal sphincter injury is most common is females and iatrogenic anal sphincter injury is most common in males.

Loperamide (imodium) is a constipating agent used as first choice pharmacological agent due to its high efficacy. Trials have suggested it thickens stool consistency and may raise resting anal sphincter pressure, associated with improved clinical function with a reduction in bowel frequency and urgency, a reduction in incontinence and less need for pads.

Loperamide is well tolerated but has been known to cause side effects of abdominal pain and distension, nausea and vomiting and constipation.

Imodium can be taken in two ways; as syrup (1mg/5mls) or tablets (2mg). There have been no comparative studies. Side effects are mainly seen with the tablet form and so it is hypothesized that the syrup form is better tolerated because it is more accurately titrated to effect.

This is a NHS funded single blinded, randomised, cross-over study to assess the clinical effects of Imodium, in tablet and syrup form, on patients presenting with faecal incontinence. Each subject will act as their own control. Patients will be recruited through out-patient visits for their FI, where they will be made aware of the trial. During the trial they will be asked to fill out FI scoring questionnaires and quality of life scores. Also they will undertake two assessments of anal physiology testing squeeze pressures, sensation and compliance at baseline and at the end after three months.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18 - 75
* Severe faecal incontinence defined as greater than one episode per week of involuntary loss of either solid or liquid stool as demonstrated by means of a baseline bowel habit and a Vaizey score of greater than 4.
* Competent and willing to fill in questionnaires and attend follow up clinics through out the study period.

Exclusion Criteria:

* Alternating bowel habit, associated with symptoms of constipation. Use of other regular or as required medications that may affect bowel function. (e.g. codeine phosphate).
* Patients with complete or partial spinal cord injuries including cauda equina syndrome.
* Active inflammatory bowel disease.
* Pregnancy
* Stoma in situ
* Psychiatric and physiological inability to comply with study protocol.
* Non english speakers (student project funding cannot cover interpreter and other costs)

(application of criteria at the discretion of the investigating doctor at initial consultation)
Acute Kidney Injury in Patients With CoVID-19

We aimed to investigate the effect of Acute Kidney Injury (AKİ) on the prognosis of patients hospitalised for COVID-19.

The effect of Acute Kidney Injury (AKİ) on the prognosis of patients hospitalised for COVID-19. Patients hospitalised for COVID-19 and acute kidney injury will be enrolled. The duration of hospitalisation, mortality rates will be compared in COVID-19 patients with and without acute kidney injury.

Eligibility Criteria:
Inclusion Criteria:

* Patients hospitalised with COVID-19.
* Patients hospitalised with COVID-19 with Acute Kidney Injury

Exclusion Criteria:

-
Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

The prevalence of functional dyspepsia (FD) is estimated to be 15% of the adult population. FD is commonly described as a condition of chronic abdominal discomfort localized to the upper abdomen. Postprandial bloating, pain, nausea, vomiting, belching, and early satiety are common symptoms of the FD patient. FD is defined by \>12 weeks of symptoms, which need not be consecutive, within the preceding year consisting of a) persistent or recurrent dyspepsia and b) an absence of organic disease after a gastrointestinal endoscopy or x-ray series. FD is therefore considered a disorder of function because no mucosal pathology is seen in these patients, as in patients with other functional disorders such as irritable bowel syndrome (IBS) and fibromyalgia (FM). There is a remarkable degree of overlap among these three disorders. These 3 disorders share the finding of hypersensitivity and the symptom of postprandial bloating to suggest the possibility of a common origin.


Eligibility Criteria:
Inclusion Criteria:

* Must have FD based on the most recent Umbrella criteria of one or more of: a. bothersome postprandial fullness, b. early satiation, c. epigastric pain, d. epigastric burning
* No evidence of organic disease (including H. pylori detected at time of endoscopy) that is likely to explain the symptoms
* Criteria must be fulfilled for the last 3 months with symptom onset at least 6 months before the diagnosis
* The physical exam, routine blood tests including CBC, chemistry panel and liver tests, upper gastrointestinal endoscopy and 24h pH study must be normal

Exclusion Criteria:

* History of IBS,rheumatoid arthritis,H. Pylori infection,lupus,peptic ulcer, cirrhosis,diabetes, HIV or TB
* Inflammatory bowel disease
* Bowel Resection (including gastric, small bowel or colon; gallbladder surgery or appendectomy are NOT exclusion criteria)
* Anti/pro-biotics last 3 months
* Previous LBT (Lactulose Breath Test)
* Narcotic Dependence
* Pregnancy
* Control subjects will be excluded if they have symptoms of heartburn, retrosternal chest pain, chronic cough, nausea or regurgitation suggestive of gastroesophageal reflux disease